At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 293 enrolled
Drug / intervention
CF101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating CF101 and Placebo for Plaque Psoriasis. Completed, enrolled 293 participants across 18 sites in 4 countries.
Detailed Summary
Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesBulgaria, Israel, Romania, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartJul 2011
Primary CompletionMar 2015
Study CompletionMay 2015
TodayJul 2026
First PostedDec 23, 2010
Enrollment StartJul 1, 2011
Primary CompletionMar 1, 2015
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 15.5 years ago
Interventions
CF101drug
orally q12h
Placebodrug
orally q12h